{"id":"NCT00489970","sponsor":"GlaxoSmithKline","briefTitle":"Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9","officialTitle":"Persistence Study of GSK Biologicals' Tdap Vaccine (776423), 1, 3, 5 and 9 Years Following Administration as a Single Dose in NCT00346073 Study and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06-01","primaryCompletion":"2011-09-01","completion":"2016-03-01","firstPosted":"2007-06-22","resultsPosted":"2010-08-11","lastUpdate":"2020-05-01"},"enrollment":1954,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Acellular Pertussis","Tetanus","Diphtheria"],"interventions":[{"type":"PROCEDURE","name":"Taking of blood samples","otherNames":[]},{"type":"BIOLOGICAL","name":"Boostrix","otherNames":[]},{"type":"BIOLOGICAL","name":"Adacel","otherNames":[]}],"arms":[{"label":"Boostrix Group","type":"EXPERIMENTAL"},{"label":"Adacel Group","type":"ACTIVE_COMPARATOR"},{"label":"Control group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the persistence of antibodies against all the vaccine antigens 1, 3, 5 and 9 years after an initial vaccination with Tdap, and also to assess immunogenicity and safety of another dose of Boostrix, administered in this study.\n\nThis protocol posting deals with objectives and outcome measures of the extension phase. The objectives and outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00346073).","primaryOutcome":{"measure":"Number of Subjects With Anti-diphtheria (Anti-D) Antibody Concentrations Greater Than or Equal to (â‰¥) Protocol Specified Cut-off","timeFrame":"At year 1 after the vaccination in primary study (NCT00346073)","effectByArm":[{"arm":"Boostrix Group","deltaMin":967,"sd":null},{"arm":"Adacel Group","deltaMin":489,"sd":null}],"pValues":[]},"eligibility":{"minAge":"28 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":13},"locations":{"siteCount":37,"countries":["United States"]},"refs":{"pmids":["30197282","21945698"],"seeAlso":["https://clinicalstudydatarequest.com","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&amp;parentIdentifier=110080&amp;attachmentIdentifier=65724607-d004-4400-b36a-3fe9c67941ee&amp;fileName=gsk-110080-clinical-study-report-redact.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":309},"commonTop":["Pain","Erythema","Fatigue","Headache","Swelling"]}}